posaconazole ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
systemic antifungal agents, miconazole derivatives 3483 171228-49-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • posaconazole
  • noxafil
  • posaconazol
  • SCH 56592
  • SCH-56592
an antifungal medicine that belongs to the triazole group, it works by preventing the formation of ergosterol, which is an important part of fungal cell walls
  • Molecular weight: 700.79
  • Formula: C37H42F2N8O4
  • CLOGP: 5.32
  • LIPINSKI: 2
  • HAC: 12
  • HDO: 1
  • TPSA: 111.79
  • ALOGS: -4.77
  • ROTB: 12

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.30 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 16.31 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 96 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 10.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 23, 2020 PMDA MSD K.K.
April 26, 2019 EMA Accord Healthcare S.L.U.
Sept. 15, 2006 FDA SCHERING

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 386.08 20.58 237 9451 97430 50498006
Pseudoaldosteronism 190.89 20.58 28 9660 31 50595405
Acute myeloid leukaemia 143.66 20.58 66 9622 15008 50580428
Drug interaction 113.92 20.58 164 9524 199457 50395979
Hepatocellular injury 112.49 20.58 67 9621 25880 50569556
Septic shock 108.78 20.58 89 9599 57086 50538350
Graft versus host disease 105.72 20.58 41 9647 6125 50589311
Neutropenia 104.72 20.58 135 9553 147830 50447606
Cholestasis 103.41 20.58 63 9625 25338 50570098
Bronchopulmonary aspergillosis 94.13 20.58 40 9648 7552 50587884
Graft versus host disease in gastrointestinal tract 87.51 20.58 29 9659 2752 50592684
Mucormycosis 82.58 20.58 27 9661 2456 50592980
Product use in unapproved indication 80.81 20.58 105 9583 115714 50479722
Fusarium infection 79.84 20.58 19 9669 531 50594905
Antibiotic level below therapeutic 71.44 20.58 11 9677 21 50595415
Acute myeloid leukaemia recurrent 71.02 20.58 21 9667 1369 50594067
Aspergillus infection 68.53 20.58 31 9657 6790 50588646
Adenoviral hepatitis 65.67 20.58 14 9674 234 50595202
Cytomegalovirus infection 61.66 20.58 40 9648 17922 50577514
Pneumonia fungal 61.08 20.58 25 9663 4295 50591141
Differentiation syndrome 60.64 20.58 17 9671 916 50594520
Left atrial hypertrophy 59.53 20.58 10 9678 40 50595396
Fungaemia 59.40 20.58 20 9668 1992 50593444
Bone marrow failure 58.88 20.58 46 9642 27578 50567858
Scedosporium infection 57.93 20.58 14 9674 418 50595018
Multiple organ dysfunction syndrome 57.67 20.58 59 9629 50278 50545158
Bicytopenia 56.19 20.58 19 9669 1917 50593519
Thrombocytopenia 54.62 20.58 92 9596 127581 50467855
Sepsis 50.63 20.58 91 9597 132834 50462602
Blood bilirubin increased 48.91 20.58 44 9644 31994 50563442
Myelosuppression 48.61 20.58 31 9657 13486 50581950
Hyperbilirubinaemia 47.51 20.58 27 9661 9543 50585893
Arthralgia 46.99 20.58 13 9675 438689 50156747
Hypokalaemia 46.70 20.58 70 9618 87922 50507514
Respiratory failure 46.22 20.58 71 9617 91110 50504326
Gastrointestinal toxicity 46.17 20.58 21 9667 4656 50590780
Electrocardiogram QT prolonged 45.77 20.58 53 9635 51833 50543603
Sinoatrial block 45.31 20.58 13 9675 762 50594674
Electrocardiogram PR shortened 44.22 20.58 10 9678 222 50595214
Aplasia 43.67 20.58 19 9669 3794 50591642
Staphylococcal sepsis 43.64 20.58 23 9665 7013 50588423
Acute kidney injury 43.27 20.58 118 9570 227940 50367496
Herpes simplex 43.25 20.58 23 9665 7139 50588297
Graft versus host disease in skin 40.30 20.58 16 9672 2540 50592896
Leukaemia recurrent 39.14 20.58 13 9675 1241 50594195
Fatigue 39.12 20.58 47 9641 707554 49887882
Neurotoxicity 36.83 20.58 27 9661 14713 50580723
Cytokine release syndrome 36.62 20.58 22 9666 8612 50586824
Pancytopenia 36.50 20.58 61 9627 83969 50511467
Joint swelling 35.81 20.58 3 9685 245283 50350153
Enterococcal infection 35.69 20.58 20 9668 6878 50588558
Systemic candida 35.57 20.58 15 9673 2775 50592661
Venoocclusive liver disease 35.46 20.58 17 9671 4244 50591192
Venous haemorrhage 34.20 20.58 8 9680 207 50595229
Coagulation test abnormal 33.61 20.58 10 9678 666 50594770
Pain 33.52 20.58 37 9651 578866 50016570
Cytomegalovirus infection reactivation 33.06 20.58 14 9674 2617 50592819
Torsade de pointes 32.59 20.58 23 9665 11812 50583624
Pyrexia 32.30 20.58 151 9537 380052 50215384
Acute lymphocytic leukaemia 31.78 20.58 13 9675 2228 50593208
Transaminases increased 30.74 20.58 32 9656 27792 50567644
Pelvic venous thrombosis 30.65 20.58 11 9677 1323 50594113
Adenovirus infection 30.56 20.58 14 9674 3154 50592282
Cholecystitis acute 29.86 20.58 18 9670 7088 50588348
Hepatic necrosis 29.30 20.58 16 9672 5232 50590204
Renal tubular acidosis 29.16 20.58 11 9677 1523 50593913
Seroconversion test positive 29.02 20.58 5 9683 24 50595412
Endophthalmitis 28.49 20.58 13 9675 2903 50592533
Long QT syndrome 28.27 20.58 13 9675 2954 50592482
Enterobacter test positive 28.12 20.58 7 9681 237 50595199
Geotrichum infection 27.99 20.58 8 9680 462 50594974
Hypersensitivity 27.94 20.58 4 9684 215157 50380279
Lung infiltration 27.87 20.58 22 9666 13371 50582065
Organ failure 27.87 20.58 12 9676 2336 50593100
Drug hypersensitivity 27.66 20.58 7 9681 251003 50344433
Graft versus host disease in liver 27.60 20.58 8 9680 486 50594950
Enterococcal bacteraemia 27.51 20.58 10 9678 1248 50594188
Hepatic failure 26.83 20.58 32 9656 32251 50563185
Acute lymphocytic leukaemia recurrent 26.46 20.58 11 9677 1964 50593472
Abdominal discomfort 26.42 20.58 6 9682 231635 50363801
Partial seizures with secondary generalisation 26.10 20.58 7 9681 319 50595117
Growth failure 26.02 20.58 7 9681 323 50595113
Hepatotoxicity 26.01 20.58 29 9659 27197 50568239
Staphylococcal infection 25.89 20.58 33 9655 35583 50559853
Atrioventricular block second degree 25.81 20.58 13 9675 3608 50591828
Graft versus host disease in lung 25.46 20.58 7 9681 351 50595085
Fungal infection 25.40 20.58 30 9658 29935 50565501
Disseminated intravascular coagulation 25.09 20.58 23 9665 17112 50578324
Systemic mycosis 25.03 20.58 9 9679 1088 50594348
Klebsiella infection 24.63 20.58 16 9672 7178 50588258
Bacteraemia 24.37 20.58 21 9667 14412 50581024
Klebsiella sepsis 24.30 20.58 9 9679 1184 50594252
Pain in extremity 24.19 20.58 11 9677 272854 50322582
Rhinocerebral mucormycosis 24.16 20.58 6 9682 201 50595235
Bacterial infection 24.13 20.58 22 9666 16259 50579177
Off label use 24.02 20.58 164 9524 474262 50121174
Soft tissue infection 23.70 20.58 10 9678 1852 50593584
Electrocardiogram ST segment depression 23.47 20.58 11 9677 2609 50592827
Kussmaul respiration 23.43 20.58 6 9682 228 50595208
Lung opacity 23.14 20.58 10 9678 1963 50593473
Overgrowth fungal 23.05 20.58 5 9683 91 50595345
Atypical pneumonia 22.75 20.58 12 9676 3663 50591773
Acquired apparent mineralocorticoid excess 22.68 20.58 3 9685 0 50595436
Chronic graft versus host disease 22.53 20.58 11 9677 2856 50592580
Pseudomonal sepsis 22.51 20.58 10 9678 2097 50593339
BK virus infection 22.48 20.58 11 9677 2870 50592566
Posterior reversible encephalopathy syndrome 21.79 20.58 20 9668 14908 50580528
Escherichia bacteraemia 21.66 20.58 11 9677 3105 50592331
Depression 21.64 20.58 3 9685 165420 50430016
Swelling 21.36 20.58 6 9682 200866 50394570
Dizziness 21.27 20.58 21 9667 346348 50249088
Neutropenic colitis 21.20 20.58 10 9678 2407 50593029
Nodal arrhythmia 21.14 20.58 8 9680 1116 50594320
Angiokeratoma 21.14 20.58 5 9683 136 50595300
Encephalopathy 21.06 20.58 29 9659 33682 50561754
Clostridium difficile colitis 20.67 20.58 21 9667 17721 50577715

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 246.92 17.75 274 12734 111966 29449553
Product use in unapproved indication 188.91 17.75 211 12797 86664 29474855
Aspergillus infection 158.14 17.75 82 12926 10499 29551020
Microsporidia infection 128.74 17.75 33 12975 530 29560989
Pseudoaldosteronism 124.94 17.75 22 12986 41 29561478
Bronchopulmonary aspergillosis 124.92 17.75 74 12934 12270 29549249
Acute myeloid leukaemia recurrent 122.14 17.75 41 12967 1739 29559780
Septic shock 117.41 17.75 141 12867 62419 29499100
Graft versus host disease 116.90 17.75 65 12943 9563 29551956
Mucormycosis 116.38 17.75 53 12955 5105 29556414
Pneumonia fungal 113.69 17.75 54 12954 5723 29555796
Fusarium infection 110.07 17.75 33 12975 964 29560555
Neutropenia 104.04 17.75 198 12810 131513 29430006
Antibiotic level below therapeutic 96.98 17.75 18 12990 51 29561468
Pathogen resistance 85.63 17.75 50 12958 8066 29553453
Cerebral aspergillosis 80.40 17.75 28 12980 1328 29560191
Drug resistance 79.61 17.75 70 12938 21470 29540049
Demodicidosis 78.62 17.75 17 12991 123 29561396
Myositis 77.16 17.75 51 12957 10232 29551287
Drug interaction 73.96 17.75 222 12786 197163 29364356
Cytokine release syndrome 72.62 17.75 54 12954 13065 29548454
Drug ineffective 70.31 17.75 330 12678 362840 29198679
Acute myeloid leukaemia 65.74 17.75 56 12952 16457 29545062
Acanthamoeba infection 64.71 17.75 18 12990 400 29561119
Off label use 64.60 17.75 282 12726 300518 29261001
Systemic mycosis 58.55 17.75 22 12986 1299 29560220
Enterococcal infection 57.21 17.75 39 12969 8229 29553290
Pseudomonas infection 56.35 17.75 43 12965 10809 29550710
Device related infection 56.14 17.75 50 12958 15586 29545933
Graft versus host disease in skin 55.72 17.75 28 12980 3351 29558168
Fungal infection 55.68 17.75 47 12961 13638 29547881
Fatigue 51.08 17.75 39 12969 316782 29244737
Thrombotic microangiopathy 50.89 17.75 37 12971 8644 29552875
Graft versus host disease in gastrointestinal tract 50.81 17.75 26 12982 3232 29558287
Cytomegalovirus infection reactivation 50.03 17.75 26 12982 3338 29558181
Neurotoxicity 49.06 17.75 45 12963 14568 29546951
Candida infection 47.48 17.75 45 12963 15180 29546339
Multiple organ dysfunction syndrome 47.36 17.75 93 12915 63023 29498496
Polymyositis 44.30 17.75 18 12990 1310 29560209
Scedosporium infection 41.93 17.75 15 12993 770 29560749
Eye infection fungal 41.31 17.75 12 12996 313 29561206
Brain abscess 40.86 17.75 21 12987 2634 29558885
Hypokalaemia 40.13 17.75 76 12932 50127 29511392
Graft versus host disease in liver 37.19 17.75 15 12993 1071 29560448
Sepsis 36.95 17.75 142 12866 142540 29418979
NPM1 gene mutation 36.87 17.75 9 12999 117 29561402
Central nervous system lesion 35.23 17.75 25 12983 5623 29555896
Fall 35.19 17.75 17 12991 177161 29384358
Hepatic cytolysis 34.63 17.75 29 12979 8318 29553201
Bronchiolitis obliterans syndrome 34.19 17.75 9 12999 161 29561358
Parainfluenzae virus infection 32.35 17.75 17 12991 2232 29559287
Immune effector cell-associated neurotoxicity syndrome 32.30 17.75 15 12993 1509 29560010
Retinal ischaemia 32.30 17.75 10 12998 326 29561193
Acute graft versus host disease in skin 32.26 17.75 22 12986 4642 29556877
Brain herniation 32.15 17.75 20 12988 3613 29557906
Treatment failure 32.12 17.75 58 12950 36881 29524638
Nephropathy toxic 32.03 17.75 31 12977 10725 29550794
Chimerism 31.46 17.75 9 12999 222 29561297
Fungal skin infection 31.32 17.75 17 12991 2381 29559138
Septic embolus 30.86 17.75 13 12995 1037 29560482
Neutrophil Pelger-Huet anomaly present 30.83 17.75 9 12999 239 29561280
Thrombocytopenia 30.75 17.75 129 12879 134694 29426825
Pyrexia 29.71 17.75 222 12786 287400 29274119
Geotrichum infection 29.54 17.75 10 12998 435 29561084
Malaise 29.20 17.75 17 12991 159585 29401934
Pain 28.98 17.75 20 12988 171412 29390107
Hyperbilirubinaemia 28.50 17.75 34 12974 14900 29546619
Neutropenic colitis 28.49 17.75 16 12992 2395 29559124
Arthralgia 28.32 17.75 13 12995 139604 29421915
Cardioactive drug level increased 28.14 17.75 14 12994 1639 29559880
Neutropenic infection 28.12 17.75 13 12995 1294 29560225
Steroid diabetes 27.76 17.75 14 12994 1687 29559832
Necrotising retinitis 27.66 17.75 11 12997 757 29560762
Cytomegalovirus infection 27.65 17.75 42 12966 23173 29538346
Immunosuppressant drug level increased 27.22 17.75 20 12988 4745 29556774
Lower respiratory tract infection fungal 26.96 17.75 10 12998 569 29560950
Differentiation syndrome 26.89 17.75 12 12996 1101 29560418
Skin necrosis 26.32 17.75 20 12988 4992 29556527
Inappropriate antidiuretic hormone secretion 26.16 17.75 28 12980 10904 29550615
Dizziness 26.09 17.75 27 12981 189657 29371862
Incorrect product formulation administered 26.03 17.75 5 13003 18 29561501
Escherichia bacteraemia 25.97 17.75 16 12992 2842 29558677
Pancytopenia 25.93 17.75 88 12920 83080 29478439
Dyspnoea 25.81 17.75 67 12941 326665 29234854
Brain compression 24.53 17.75 7 13001 171 29561348
Lymphopenia 24.50 17.75 30 12978 13503 29548016
Myocardial infarction 24.41 17.75 9 12999 110287 29451232
Enterobacter bacteraemia 24.27 17.75 8 13000 320 29561199
Septic encephalopathy 24.23 17.75 6 13002 83 29561436
Product use issue 24.20 17.75 63 12945 51381 29510138
Nocardiosis 24.04 17.75 16 12992 3244 29558275
Cerebral artery embolism 23.47 17.75 10 12998 820 29560699
Ileus paralytic 23.45 17.75 19 12989 5204 29556315
Ecthyma 23.18 17.75 8 13000 369 29561150
Gastrointestinal tract mucosal pigmentation 23.06 17.75 8 13000 375 29561144
Viral haemorrhagic cystitis 22.28 17.75 10 12998 930 29560589
Renal tubular disorder 22.05 17.75 17 12991 4335 29557184
Bacteraemia 21.55 17.75 31 12977 16292 29545227
Folliculitis 21.45 17.75 16 12992 3884 29557635
Systemic candida 21.36 17.75 14 12994 2766 29558753
Intracranial mass 21.16 17.75 10 12998 1046 29560473
Bacterial infection 20.73 17.75 27 12981 12921 29548598
Depression 20.50 17.75 6 13002 85141 29476378
Gastrointestinal wall thinning 20.49 17.75 4 13004 16 29561503
Staphylococcal bacteraemia 20.32 17.75 20 12988 7059 29554460
Blood immunoglobulin G decreased 20.28 17.75 10 12998 1149 29560370
Cerebral ventricle collapse 20.27 17.75 5 13003 68 29561451
Necrotising ulcerative gingivostomatitis 20.14 17.75 5 13003 70 29561449
Blood pressure increased 20.12 17.75 4 13004 73799 29487720
Encephalopathy 20.02 17.75 43 12965 31000 29530519
Acute graft versus host disease 19.67 17.75 18 12990 5806 29555713
Product dose omission issue 19.49 17.75 9 12999 96374 29465145
Cerebrovascular accident 19.30 17.75 5 13003 76906 29484613
Stenotrophomonas infection 19.23 17.75 11 12997 1706 29559813
Pneumonia 19.21 17.75 220 12788 319952 29241567
Weight increased 19.21 17.75 5 13003 76662 29484857
Donor leukocyte infusion 19.15 17.75 4 13004 24 29561495
Escherichia sepsis 19.08 17.75 15 12993 3934 29557585
Acute graft versus host disease in liver 18.92 17.75 10 12998 1328 29560191
Polyomavirus-associated nephropathy 18.83 17.75 14 12994 3382 29558137
Drug ineffective for unapproved indication 18.77 17.75 27 12981 14187 29547332
Acute graft versus host disease in intestine 18.50 17.75 12 12996 2329 29559190
Aspergillus test positive 18.41 17.75 7 13001 427 29561092
Citrobacter infection 18.28 17.75 7 13001 435 29561084
SARS-CoV-2 RNA 18.26 17.75 4 13004 31 29561488
Bordetella infection 18.24 17.75 5 13003 105 29561414
Microsporum infection 18.14 17.75 4 13004 32 29561487
Drug hypersensitivity 18.04 17.75 4 13004 68402 29493117
Pruritus 17.97 17.75 15 12993 116834 29444685
Adenovirus reactivation 17.81 17.75 5 13003 115 29561404
Tumour lysis syndrome 17.79 17.75 26 12982 13858 29547661

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 577.49 17.22 483 20690 187174 64290385
Pseudoaldosteronism 294.14 17.22 49 21124 87 64477472
Product use in unapproved indication 282.82 17.22 318 20855 176300 64301259
Neutropenia 229.17 17.22 334 20839 239290 64238269
Mucormycosis 213.32 17.22 83 21090 7258 64470301
Aspergillus infection 212.66 17.22 105 21068 16274 64461285
Septic shock 211.24 17.22 214 20959 105223 64372336
Bronchopulmonary aspergillosis 186.27 17.22 101 21072 18984 64458575
Graft versus host disease 183.64 17.22 90 21083 13723 64463836
Pneumonia fungal 181.45 17.22 78 21095 8799 64468760
Drug interaction 177.45 17.22 376 20797 361707 64115852
Acute myeloid leukaemia recurrent 159.12 17.22 52 21121 2732 64474827
Fusarium infection 152.26 17.22 44 21129 1525 64476034
Acute myeloid leukaemia 152.25 17.22 101 21072 27362 64450197
Microsporidia infection 127.42 17.22 33 21140 752 64476807
Graft versus host disease in gastrointestinal tract 113.66 17.22 49 21124 5563 64471996
Cytokine release syndrome 104.44 17.22 72 21101 20757 64456802
Pathogen resistance 96.97 17.22 57 21116 12486 64465073
Scedosporium infection 94.82 17.22 29 21144 1225 64476334
Fatigue 91.16 17.22 68 21105 748662 63728897
Multiple organ dysfunction syndrome 90.36 17.22 137 21036 101276 64376283
Arthralgia 89.99 17.22 18 21155 442242 64035317
Cholestasis 85.95 17.22 89 21084 44783 64432776
Sepsis 84.70 17.22 214 20959 230127 64247432
Enterococcal infection 84.18 17.22 54 21119 13812 64463747
Graft versus host disease in skin 83.73 17.22 39 21134 5308 64472251
Demodicidosis 81.96 17.22 17 21156 137 64477422
Hypokalaemia 79.38 17.22 143 21030 121760 64355799
Cytomegalovirus infection 78.95 17.22 78 21095 37121 64440438
Neurotoxicity 78.62 17.22 68 21105 27336 64450223
Systemic mycosis 77.29 17.22 29 21144 2294 64475265
Pseudomonas infection 76.23 17.22 56 21117 17827 64459732
Device related infection 75.98 17.22 70 21103 30556 64447003
Drug resistance 73.38 17.22 73 21100 35029 64442530
Cytomegalovirus infection reactivation 72.02 17.22 36 21137 5720 64471839
Acanthamoeba infection 71.99 17.22 19 21154 467 64477092
Pain 71.58 17.22 47 21126 553464 63924095
Myositis 71.43 17.22 52 21121 16325 64461234
Hepatocellular injury 71.37 17.22 81 21092 45154 64432405
Thrombocytopenia 71.14 17.22 197 20976 223604 64253955
Differentiation syndrome 69.65 17.22 26 21147 2028 64475531
Fungal infection 65.70 17.22 68 21105 34183 64443376
Hyperbilirubinaemia 63.64 17.22 54 21119 21151 64456408
Cerebral aspergillosis 63.20 17.22 23 21150 1670 64475889
Off label use 62.92 17.22 388 20785 632418 63845141
Graft versus host disease in liver 61.51 17.22 22 21151 1519 64476040
Pyrexia 58.97 17.22 348 20825 558296 63919263
Brain abscess 57.83 17.22 28 21145 4153 64473406
Pancytopenia 57.75 17.22 138 21035 143171 64334388
Geotrichum infection 55.93 17.22 18 21155 900 64476659
Thrombotic microangiopathy 55.36 17.22 45 21128 16610 64460949
Joint swelling 52.56 17.22 5 21168 215377 64262182
Hypersensitivity 52.38 17.22 3 21170 196449 64281110
Left atrial hypertrophy 52.32 17.22 10 21163 50 64477509
Nasopharyngitis 52.26 17.22 3 21170 196070 64281489
Systemic candida 51.41 17.22 28 21145 5301 64472258
Drug ineffective 51.39 17.22 459 20714 839788 63637771
Fungaemia 51.30 17.22 25 21148 3760 64473799
Respiratory failure 51.28 17.22 142 21031 161041 64316518
Fall 50.38 17.22 38 21135 416788 64060771
Malaise 49.34 17.22 35 21138 396212 64081347
Candida infection 49.11 17.22 56 21117 31363 64446196
Escherichia bacteraemia 48.30 17.22 27 21146 5376 64472183
Dyspnoea 47.98 17.22 103 21070 718571 63758988
Dizziness 47.31 17.22 43 21130 430120 64047439
Bone marrow failure 47.31 17.22 68 21105 47884 64429675
Drug hypersensitivity 45.62 17.22 11 21162 237804 64239755
Staphylococcal sepsis 45.31 17.22 36 21137 12863 64464696
Adenoviral hepatitis 44.85 17.22 13 21160 455 64477104
Neutropenic colitis 44.00 17.22 24 21149 4557 64473002
Immune effector cell-associated neurotoxicity syndrome 43.98 17.22 20 21153 2575 64474984
NPM1 gene mutation 43.87 17.22 10 21163 130 64477429
Staphylococcal infection 43.04 17.22 67 21106 50611 64426948
Venoocclusive liver disease 41.86 17.22 31 21142 9984 64467575
Bacterial infection 41.61 17.22 46 21127 24904 64452655
Leukaemia recurrent 40.86 17.22 19 21154 2575 64474984
Renal tubular disorder 40.56 17.22 25 21148 5962 64471597
Abdominal discomfort 40.12 17.22 6 21167 182316 64295243
Blood pressure increased 39.57 17.22 5 21168 172547 64305012
Aplasia 39.55 17.22 26 21147 6927 64470632
Bacteraemia 38.77 17.22 46 21127 26865 64450694
Graft versus host disease in lung 37.93 17.22 13 21160 791 64476768
Acquired apparent mineralocorticoid excess 37.90 17.22 7 21166 28 64477531
Bronchiolitis obliterans syndrome 37.57 17.22 10 21163 254 64477305
Pneumonia 37.37 17.22 312 20861 559264 63918295
Electrocardiogram PR shortened 37.28 17.22 10 21163 262 64477297
Chimerism 37.13 17.22 10 21163 266 64477293
Polymyositis 37.03 17.22 18 21155 2692 64474867
Eye infection fungal 36.54 17.22 11 21162 440 64477119
Myelosuppression 36.44 17.22 42 21131 23788 64453771
Depression 36.09 17.22 8 21165 183283 64294276
Encephalopathy 35.72 17.22 67 21106 58752 64418807
BK virus infection 35.69 17.22 25 21148 7387 64470172
Transaminases increased 35.17 17.22 57 21116 44537 64433022
Acute graft versus host disease in skin 35.07 17.22 24 21149 6831 64470728
Ileus paralytic 35.07 17.22 26 21147 8389 64469170
Stenotrophomonas infection 34.85 17.22 18 21155 3062 64474497
Hepatic cytolysis 34.62 17.22 32 21141 14017 64463542
Klebsiella sepsis 34.52 17.22 17 21156 2615 64474944
Electrocardiogram QT prolonged 33.60 17.22 78 21095 79370 64398189
Pruritus 33.40 17.22 32 21141 312368 64165191
Infusion related reaction 32.74 17.22 7 21166 164460 64313099
Lung infiltration 32.25 17.22 37 21136 20852 64456707
Nephropathy toxic 32.20 17.22 34 21139 17480 64460079
Acute graft versus host disease in intestine 32.17 17.22 18 21155 3591 64473968
Bicytopenia 32.11 17.22 18 21155 3604 64473955
Weight increased 31.99 17.22 15 21158 213333 64264226
Inappropriate antidiuretic hormone secretion 31.94 17.22 38 21135 22251 64455308
Immunosuppressant drug level increased 31.54 17.22 23 21150 7236 64470323
Brain herniation 31.37 17.22 22 21151 6511 64471048
Gastrointestinal toxicity 30.51 17.22 20 21153 5302 64472257
Klebsiella infection 30.33 17.22 29 21144 13252 64464307
Neutrophil Pelger-Huet anomaly present 30.29 17.22 9 21164 344 64477215
Cytopenia 30.17 17.22 31 21142 15440 64462119
Parainfluenzae virus infection 30.10 17.22 19 21154 4724 64472835
Hepatotoxicity 30.05 17.22 50 21123 39912 64437647
Herpes simplex 29.92 17.22 26 21147 10510 64467049
Neutropenic infection 29.73 17.22 14 21159 1951 64475608
Enterobacter bacteraemia 29.64 17.22 10 21163 580 64476979
Swelling 29.58 17.22 8 21165 160210 64317349
Nausea 28.58 17.22 147 21026 785653 63691906
Venous haemorrhage 28.23 17.22 8 21165 258 64477301
Posterior reversible encephalopathy syndrome 27.87 17.22 36 21137 22910 64454649
Acute lymphocytic leukaemia recurrent 27.75 17.22 17 21156 4009 64473550
Hyperhidrosis 27.73 17.22 4 21169 124916 64352643
Retinal ischaemia 27.69 17.22 10 21163 710 64476849
Tumour lysis syndrome 27.62 17.22 33 21140 19407 64458152
Nocardiosis 27.54 17.22 18 21155 4749 64472810
Weight decreased 27.48 17.22 32 21141 285707 64191852
Necrotising retinitis 27.31 17.22 11 21162 1052 64476507
Pain in extremity 26.99 17.22 36 21137 303049 64174510
Organ failure 26.74 17.22 16 21157 3617 64473942
Enterococcal bacteraemia 26.51 17.22 14 21159 2491 64475068
Fungal skin infection 26.35 17.22 18 21155 5107 64472452
Muscle spasms 26.11 17.22 7 21166 141016 64336543
Lower respiratory tract infection fungal 26.01 17.22 10 21163 845 64476714
Feeling abnormal 25.96 17.22 6 21167 133596 64343963
Steroid diabetes 25.69 17.22 14 21159 2652 64474907
Blood immunoglobulin G decreased 25.61 17.22 14 21159 2669 64474890
Sinusitis fungal 25.34 17.22 12 21161 1694 64475865
Peripheral swelling 25.31 17.22 19 21154 209134 64268425
Hepatic failure 25.21 17.22 56 21117 55338 64422221
Septic embolus 24.97 17.22 12 21161 1750 64475809
Rash 24.84 17.22 73 21100 458476 64019083
Cardioactive drug level increased 24.83 17.22 15 21158 3450 64474109
Growth failure 24.78 17.22 7 21166 223 64477336
Product dose omission issue 24.46 17.22 17 21156 194730 64282829
Septic encephalopathy 24.35 17.22 7 21166 238 64477321
Drug level decreased 24.17 17.22 24 21149 11479 64466080
Adenovirus reactivation 24.10 17.22 7 21166 247 64477312
Blood bilirubin increased 23.77 17.22 56 21117 57497 64420062
Microsporum infection 23.61 17.22 5 21168 45 64477514
Central nervous system lesion 23.57 17.22 24 21149 11825 64465734
Seroconversion test positive 23.51 17.22 5 21168 46 64477513
Coagulation test abnormal 23.41 17.22 10 21163 1109 64476450
Cerebrovascular accident 23.35 17.22 8 21165 137575 64339984
Product administered to patient of inappropriate age 23.28 17.22 16 21157 4585 64472974
Hypomagnesaemia 23.22 17.22 43 21130 37333 64440226
Cerebral artery embolism 22.90 17.22 11 21162 1603 64475956
Respiratory syncytial virus infection 22.82 17.22 19 21154 7249 64470310
Viral haemorrhagic cystitis 22.76 17.22 11 21162 1624 64475935
Insomnia 22.64 17.22 19 21154 197817 64279742
Staphylococcal bacteraemia 22.49 17.22 22 21151 10333 64467226
Pneumonia pseudomonal 22.36 17.22 16 21157 4887 64472672
Drug ineffective for unapproved indication 22.14 17.22 38 21135 31095 64446464
Long QT syndrome 21.69 17.22 16 21157 5123 64472436
Pseudomonal sepsis 21.60 17.22 16 21157 5156 64472403
Anxiety 21.36 17.22 21 21152 202628 64274931
Gastrointestinal wall thinning 21.10 17.22 4 21169 19 64477540
Chronic graft versus host disease 20.94 17.22 17 21156 6259 64471300
Adenovirus infection 20.79 17.22 18 21155 7237 64470322
Soft tissue infection 20.67 17.22 13 21160 3210 64474349
Retinal haemorrhage 20.49 17.22 18 21155 7380 64470179
Clostridium difficile colitis 20.38 17.22 34 21139 27189 64450370
Gait disturbance 20.36 17.22 16 21157 172139 64305420
Pneumonia klebsiella 20.33 17.22 14 21159 4023 64473536
Polyomavirus-associated nephropathy 20.14 17.22 15 21158 4873 64472686
Overgrowth fungal 20.11 17.22 5 21168 96 64477463
Back pain 20.02 17.22 32 21141 250139 64227420
Toxic skin eruption 19.97 17.22 28 21145 19256 64458303
Skin necrosis 19.83 17.22 24 21149 14305 64463254
Citrobacter infection 19.70 17.22 8 21165 781 64476778
Candida sepsis 19.55 17.22 11 21162 2217 64475342
Bordetella infection 19.51 17.22 5 21168 109 64477450
Pulmonary mucormycosis 19.48 17.22 8 21165 804 64476755
Pneumonia cytomegaloviral 19.42 17.22 14 21159 4325 64473234
SARS-CoV-2 RNA 19.42 17.22 4 21169 31 64477528
Acute lymphocytic leukaemia 19.33 17.22 14 21159 4357 64473202
Drug-induced liver injury 19.29 17.22 46 21127 47597 64429962
Brain compression 19.16 17.22 7 21166 514 64477045
Lymphopenia 19.15 17.22 32 21141 25625 64451934
Renal tubular acidosis 19.07 17.22 12 21161 2967 64474592
Cholecystitis acute 19.03 17.22 21 21152 11339 64466220
Pelvic venous thrombosis 19.02 17.22 10 21163 1763 64475796
Escherichia sepsis 18.98 17.22 17 21156 7148 64470411
Cerebral ventricle collapse 18.98 17.22 5 21168 122 64477437
Streptococcal bacteraemia 18.75 17.22 12 21161 3055 64474504
Acute kidney injury 18.53 17.22 227 20946 449013 64028546
Gastrointestinal tract mucosal pigmentation 18.46 17.22 8 21165 919 64476640
Enterococcal sepsis 18.40 17.22 11 21162 2483 64475076
Renal failure 18.28 17.22 112 21061 181576 64295983
Cell death 17.96 17.22 13 21160 4041 64473518
Intracranial mass 17.69 17.22 10 21163 2033 64475526
Myocardial infarction 17.68 17.22 17 21156 165804 64311755
Torsade de pointes 17.67 17.22 25 21148 17338 64460221
Febrile bone marrow aplasia 17.48 17.22 20 21153 11235 64466324
Encephalitis fungal 17.45 17.22 5 21168 168 64477391
Peripheral sensory neuropathy 17.30 17.22 20 21153 11358 64466201
Encephalitis 17.30 17.22 21 21152 12550 64465009

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J02AC04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Triazole and tetrazole derivatives
FDA CS M0002083 Azoles
FDA EPC N0000175487 Azole Antifungal
MeSH PA D058888 14-alpha Demethylase Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D065088 Steroid Synthesis Inhibitors
MeSH PA D014344 Trypanocidal Agents
CHEBI has role CHEBI:36335 trypanocidal drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Mycosis indication 3218000 DOID:1564
Coccidioidomycosis indication 60826002 DOID:13450
Fusarium infection indication 64250002
Aspergillosis indication 65553006 DOID:13564
Mucormycosis indication 76627001
Candidiasis indication 78048006 DOID:1508
Chromoblastomycosis indication 187079000
Mycetoma indication 410039003 DOID:13078




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Otitis externa caused by yeast, Malassezia pachydermatis Indication
Dogs Otitis externa associated with bacteria coagulase positive staphylococci Indication
Dogs Otitis externa associated with Pseudomonas aeruginosa Indication
Dogs Otitis externa associated with Enterococcus faecalis Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Posatex Otic Suspension Intervet Inc. 3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.68 acidic
pKa2 5.12 Basic
pKa3 5.0 Basic
pKa4 2.66 Basic
pKa5 0.3 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS 9358297 June 24, 2031 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WHO ARE SEVERELY IMMUNOCOMPROMISED
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS 9358297 June 24, 2031 TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS 9023790 July 4, 2031 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS 9023790 July 4, 2031 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WHO ARE SEVERELY IMMUNOCOMPROMISED
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS 9023790 July 4, 2031 TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG NOXAFIL MERCK SHARP DOHME N205053 Nov. 25, 2013 RX TABLET, DELAYED RELEASE ORAL May 31, 2024 NEW PATIENT POPULATION
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS May 31, 2024 NEW PATIENT POPULATION
300MG NOXAFIL POWDERMIX KIT MSD MERCK CO N214770 May 31, 2021 DISCN FOR SUSPENSION, DELAYED RELEASE ORAL May 31, 2024 NEW PRODUCT
100MG NOXAFIL MERCK SHARP DOHME N205053 Nov. 25, 2013 RX TABLET, DELAYED RELEASE ORAL June 17, 2024 FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS 13 YEARS OF AGE AND OLDER
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS June 17, 2024 FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS 13 YEARS OF AGE AND OLDER
100MG NOXAFIL MERCK SHARP DOHME N205053 Nov. 25, 2013 RX TABLET, DELAYED RELEASE ORAL June 17, 2028 FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS June 17, 2028 FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Enzyme IC50 5.42 CHEMBL
Cytochrome P450 3A4 Enzyme WOMBAT-PK
Lanosterol 14-alpha demethylase Enzyme INHIBITOR MIC 9.40 WOMBAT-PK CHEMBL
14-alpha sterol demethylase Cyp51A Enzyme Kd 5.57 CHEMBL
14-alpha sterol demethylase Enzyme Kd 7.14 CHEMBL
Sterol 14-alpha demethylase Enzyme IC50 7.32 CHEMBL
Sterol 14-alpha-demethylase Enzyme Kd 6.88 CHEMBL
14-alpha sterol demethylase Enzyme Kd 6.88 CHEMBL
14-alpha sterol demethylase Enzyme Kd 6.88 CHEMBL

External reference:

IDSource
4025699 VUID
N0000179745 NUI
D02555 KEGG_DRUG
4025699 VANDF
C0936148 UMLSCUI
CHEBI:64355 CHEBI
X2N PDB_CHEM_ID
CHEMBL1397 ChEMBL_ID
DB01263 DRUGBANK_ID
C101425 MESH_SUPPLEMENTAL_RECORD_UI
11428 IUPHAR_LIGAND_ID
7713 INN_ID
6TK1G07BHZ UNII
468595 PUBCHEM_CID
282446 RXNORM
21768 MMSL
320488 MMSL
83903 MMSL
d05853 MMSL
011210 NDDF
420282006 SNOMEDCT_US
421747003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-1328 SUSPENSION 40 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-1328 SUSPENSION 40 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-2224 POWDER, FOR SUSPENSION 300 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-2224 POWDER, FOR SUSPENSION 300 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-4324 TABLET, COATED 100 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-4324 TABLET, COATED 100 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-4331 SOLUTION 18 mg INTRAVENOUS NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-4331 SOLUTION 18 mg INTRAVENOUS NDA 31 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0254-2045 TABLET, COATED 100 mg ORAL NDA authorized generic 32 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0406-7711 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 33 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0527-2133 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 28 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7149 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 26 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7149 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 26 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16714-156 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 28 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 17856-2133 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 28 sections
Posaconazole HUMAN PRESCRIPTION DRUG LABEL 1 43598-470 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 27 sections
Posaconazole HUMAN PRESCRIPTION DRUG LABEL 1 50268-683 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 27 sections
Posaconazole HUMAN PRESCRIPTION DRUG LABEL 1 60687-523 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 29 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 63629-2236 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 63629-2236 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 70377-038 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 29 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 70377-038 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 29 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 70748-258 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 26 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 70748-258 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 26 sections